UK markets open in 4 hours 45 minutes
  • NIKKEI 225

    28,876.81
    +5.03 (+0.02%)
     
  • HANG SENG

    20,051.82
    +10.96 (+0.05%)
     
  • CRUDE OIL

    88.81
    -0.60 (-0.67%)
     
  • GOLD FUTURES

    1,795.90
    -2.20 (-0.12%)
     
  • DOW

    33,912.44
    +151.39 (+0.45%)
     
  • BTC-GBP

    20,039.67
    -542.86 (-2.64%)
     
  • CMC Crypto 200

    574.08
    -16.68 (-2.82%)
     
  • ^IXIC

    13,128.05
    +80.87 (+0.62%)
     
  • ^FTAS

    4,155.09
    +5.19 (+0.13%)
     

Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2015-2022 Featuring Abbott, AstraZeneca, Pfizer & Hundreds More

·4-min read
Company Logo
Company Logo

Dublin, Aug. 05, 2022 (GLOBE NEWSWIRE) -- The "Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2015-2022" report has been added to ResearchAndMarkets.com's offering.

The Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2015-2022 report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals and provides details of the latest clinical agreements announced in the healthcare sector.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of over 2,900 clinical stage partnering deals announced since 2015 including financial terms where available including numerous links to online deal records of actual clinical partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

The report also includes numerous tables and figures that illustrate the trends and activities in clinical stage partnering and deal making since 2015.

In addition, a comprehensive appendix of all clinical stage deals since 2015 is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of clinical stage products and compounds.

Key benefits
Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2015- 2022 provides the reader with the following key benefits:

  • In-depth understanding of clinical stage deal trends since 2015

  • Access to headline, upfront, milestone and royalty data

  • Analysis of the structure of clinical stage agreements with numerous real life case studies

  • Insight into the terms included in a clinical stage agreement, together with real world clause examples

  • Understand the key deal terms companies have agreed in previous deals

  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope
Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2015- 2022 is intended to provide the reader with an in-depth understanding and access to clinical stage deal trends and structure of deals entered into by leading companies worldwide.

Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2015- 2022 includes:

  • Trends in clinical stage dealmaking in the biopharma industry since 2015

  • Analysis of clinical stage deal structure

  • Access to headline, upfront, milestone and royalty data

  • Case studies of real-life clinical stage deals

  • Access to over 2,900 clinical stage deals

  • The leading clinical stage deals by value since 2015

  • Most active clinical stage dealmakers since 2015

  • The leading clinical stage partnering resources

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Why do companies partner clinical stage compounds?

Chapter 3 - Clinical stage deal strategies and structure

Chapter 4 - Clinical stage partnering payment strategies

Chapter 5 - Trends in clinical stage deal making

Chapter 6 - Payment terms for clinical stage partnering

Chapter 7 - Leading clinical stage deals

Chapter 8 - Top 25 most active clinical stage dealmakers

Chapter 9 - Clinical stage partnering contracts directory

Chapter 10 - Clinical stage deal making by development stage


For more information about this report visit https://www.researchandmarkets.com/r/87s0nz

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting